Xuedong Wei
Papers
1
Total Citations
2
H-Index
1
About
Xuedong Wei is a leading clinical researcher in urologic oncology, with a primary focus on high-risk localized prostate cancer. His most impactful work centers on evaluating novel neoadjuvant therapies to improve surgical outcomes for patients with high-risk and very high-risk localized prostate cancer (HRLPC/VHRLPC). In his landmark 2024 multicenter, open-labeled, single-arm Phase II trial, Dr. Wei investigated the efficacy and safety of neoadjuvant darolutamide combined with androgen deprivation therapy (ADT) prior to radical prostatectomy. This study addresses a critical unmet need, as standard upfront surgery in these patients is associated with adverse outcomes and a high risk of disease progression. By demonstrating the potential of this intensified hormonal approach to improve pathological responses, Dr. Wei’s work provides a promising strategy to reduce surgical morbidity and lower recurrence rates. His research, already garnering citations, is shaping the perioperative management of aggressive prostate cancer and offers a pathway toward more effective, personalized treatment protocols for this challenging patient population.
Research Focus
Key Achievements
Top Papers
- 1